Latest news with #MJFF
Yahoo
28-05-2025
- Business
- Yahoo
IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757
GOTHENBURG, SE / / May 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, today announces the company has successfully completed the second and final part of its clinical Phase I study, in which the drug candidate IRL757, being developed for the treatment of apathy, was administered in multiple ascending doses (MAD). The results show that IRL757 is well absorbed and provides good exposure in the body following ten days of dosing. All participants completed the study, and no serious adverse events were recorded. The safety, tolerability and pharmacokinetic profile of IRL757 support continued clinical development. "We are very pleased that IRL757 is well absorbed and provides good exposure in the body while demonstrating excellent tolerability and a favorable safety profile. These results give us a strong foundation for the continued clinical development of the drug candidate, which has the potential to treat and counteract apathy in millions of patients with neurodegenerative diseases," says Dr. Joakim Tedroff, MD, Chief Medical Officer at IRLAB. The Phase I study has been funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) through a grant of just over SEK 20 million. MJFF is the world's largest non-profit funder of Parkinson's disease research, and the organization's support for IRL757 means a strong external validation of the project's goals and potential. Based on the positive results from the completed Phase I studies, a clinical Phase Ib study in Parkinson's disease and apathy has been initiated in cooperation with The McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. The first patients are expected to be enrolled in the study in the second half of 2025. IRLAB and MSRD formed a collaboration in May 2024 to advance IRL757 through proof-of-concept trials as a potential treatment of apathy. Apathy is characterized by indifference, resignation and a lack of response to what is happening in the outside world. The condition often leads to significant disability and caregiver distress, affecting a substantial proportion of people living with Parkinson's, Alzheimer's and other diseases related to the central nervous system. Currently, there are no drugs on the market to treat apathy. IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This effect is believed to be associated with the drug candidate's unique ability to counteract disturbances in central nervous system nerve signaling proposed to underly apathy in several neurological conditions. Om Fas I-studienThe Phase I study consists of two parts and aims to document the safety, tolerability and pharmacokinetic properties of IRL757 in healthy subjects. In the first part of the study, single ascending doses of the drug candidate are administered (SAD) and in the second part, multiple ascending doses are given (MAD). In addition, the possible influence of concomitant food intake will be documented. For more information Kristina Torfgård, CEOPhone: +46 730 60 70 99E-mail: About IRL757 The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's disease and other neurological conditions. Apathy, a widespread and debilitating issue, affects over 20 million people in the U.S. and Europe alone without a currently available treatment. The prevalence is high, occurring in 1.1-4 million people (20-70 percent) being treated with Parkinson's in the eight major markets (China, EU5, Japan, and the US), and in 4.9-6.7 million people (43-59 percent) being treated for Alzheimer's disease in the ten major markets (Canada, China, EU5, Japan, South Korea, and the US). IRL757 has the potential to become the first treatment for apathy. The efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signalling, a key factor believed to contribute to apathy in neurological disorders. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments IRLAB reports positive results from the second part of a Phase I study with IRL757 SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire
Cision Canada
15-05-2025
- Business
- Cision Canada
MICHAEL J. FOX VOICES REAL CANADIAN SUPERSTORE'S ODE TO CANADIAN UNITY AND STRENGTH
BRAMPTON, ON, May 14, 2025 /CNW/ - Real Canadian Superstore is proud to launch a new national campaign celebrating the resilience and pride of Canadians. Featuring a powerful brand spot voiced by iconic Canadian actor Michael J. Fox, Real Canadian Superstore highlights the importance of unity and standing together. The commercial showcases the Canadian flag flying proudly above a Real Canadian Superstore, symbolizing the brand's deep commitment to its Canadian heritage and values. Fox's narration emphasizes the strength and spirit of Canadians, reminding viewers that collective action is key to overcoming adversity. "Real Canadian Superstore is a proudly Canadian brand, and we wanted to create a message that resonates with the values we share with our customers," says Shelley Tangney, VP of Marketing at Real Canadian Superstore. "Michael J. Fox embodies the Canadian spirit of resilience, and we are honoured to have him lend his voice to this message." The campaign also includes a second commercial that shines a spotlight on the dedicated Real Canadian Superstore colleagues working in communities across the country, to the musical backdrop of iconic Canadian band Rush's track The Spirit of the Radio. These Real Canadian Superstore individuals are the backbone of the stores, ensuring that Canadians have access to essential products and services, including thousands of local products on store shelves. "Real Canadian Superstore is a proudly Canadian brand that's doing a lot to help Canadians unite during a trying time. This spot is about standing together and celebrating Canadian pride," says Bryan Collins, Co-Founder and Chief Creative Officer at ONE23WEST, who collaborated with Real Canadian Superstore on the campaign. "There are few people who embody Canadian resilience more than Michael J. Fox." To further demonstrate its commitment to Canadian values, Real Canadian Superstore is making a $100,000 donation to The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support its important work in Parkinson's research. Since its founding in 2000, MJFF has funded more than $2.5 billion in global research, including in Canada, fundamentally altering the trajectory of progress toward a cure. About Loblaw Companies Limited Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy, health and beauty, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,500 corporate franchised and Associate-owned locations, Loblaw, its franchisees, and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers. Loblaw's purpose – Live Life Well ® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart ® and Pharmaprix ® locations and close to 500 Loblaw locations; PC Financial ® services; affordable Joe Fresh ® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand ®, Farmer's Market™, no name ® and President's Choice ®.
Yahoo
15-05-2025
- Business
- Yahoo
MICHAEL J. FOX VOICES REAL CANADIAN SUPERSTORE'S ODE TO CANADIAN UNITY AND STRENGTH
BRAMPTON, ON, May 14, 2025 /CNW/ - Real Canadian Superstore is proud to launch a new national campaign celebrating the resilience and pride of Canadians. Featuring a powerful brand spot voiced by iconic Canadian actor Michael J. Fox, Real Canadian Superstore highlights the importance of unity and standing together. The commercial showcases the Canadian flag flying proudly above a Real Canadian Superstore, symbolizing the brand's deep commitment to its Canadian heritage and values. Fox's narration emphasizes the strength and spirit of Canadians, reminding viewers that collective action is key to overcoming adversity. "Real Canadian Superstore is a proudly Canadian brand, and we wanted to create a message that resonates with the values we share with our customers," says Shelley Tangney, VP of Marketing at Real Canadian Superstore. "Michael J. Fox embodies the Canadian spirit of resilience, and we are honoured to have him lend his voice to this message." The campaign also includes a second commercial that shines a spotlight on the dedicated Real Canadian Superstore colleagues working in communities across the country, to the musical backdrop of iconic Canadian band Rush's track The Spirit of the Radio. These Real Canadian Superstore individuals are the backbone of the stores, ensuring that Canadians have access to essential products and services, including thousands of local products on store shelves. "Real Canadian Superstore is a proudly Canadian brand that's doing a lot to help Canadians unite during a trying time. This spot is about standing together and celebrating Canadian pride," says Bryan Collins, Co-Founder and Chief Creative Officer at ONE23WEST, who collaborated with Real Canadian Superstore on the campaign. "There are few people who embody Canadian resilience more than Michael J. Fox." To further demonstrate its commitment to Canadian values, Real Canadian Superstore is making a $100,000 donation to The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support its important work in Parkinson's research. Since its founding in 2000, MJFF has funded more than $2.5 billion in global research, including in Canada, fundamentally altering the trajectory of progress toward a cure. About Loblaw Companies Limited Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy, health and beauty, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,500 corporate franchised and Associate-owned locations, Loblaw, its franchisees, and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers. Loblaw's purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and close to 500 Loblaw locations; PC Financial® services; affordable Joe Fresh® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand®, Farmer's Market™, no name® and President's Choice®. Videos: , SOURCE Loblaw Companies Limited View original content to download multimedia:
Forbes
05-05-2025
- Health
- Forbes
How The Shortage Of Parkinson's Disease Specialists Is Changing
So far, the Edmond J. Safra Fellowship in Movement Disorders has trained 40 new ... More clinician-researchers. it was the result of the Michael J. Fox Foundation and the Edmond J. Safra Foundation partnering together to address Parkinson's Disease research and care.. Pictured here is Lily Safra and Michael J. Fox cutting the ribbon to launch the partnership in 2014. (Photo: Courtesy of Kristina Magana/Michael J. Fox Foundation) Parkinson's disease is a complex condition. It's complex to diagnose and complex to handle in oh so many ways. It's complex to do research and develop new treatments for this complex problem as well. And when something is complex, that's when you call in people who know all the relevant issues through and through. Yet, there just hasn't been enough PD specialists in the U.S. for the one million or so people in the country who currently are dealing with PD and the many more that will have the condition in the future. But the Michael J. Fox Foundation and the Edmond J. Safra Foundation have been training their sights on trying to change the PD specialist training situation in the U.S. and beyond. Deborah W. Brooks, chief executive officer and co-founder of MJFF, recalled what happened when the Safra Foundation first came to ask for opinion. 'They wanted to support great PD care and research centers, coming through the lens of science support. We said what if we shaped it as a way to train future researchers and care providers.' Brooks continued by saying, 'We don't have many movement disorder specialists, especially those active in research.' That was a little over a decade ago. Such conversations eventually led to the 2014 launch of the Edmond J. Safra Fellowship in Movement Disorders, which has since trained 40 new clinician-researchers. These graduates of the training fellowship have in turn reached 31,200 different patients with PD so far by their estimates. Now, this partnership will keep the train going, so to speak. The two foundations have just announced that this fellowship will stretch into 2031, which would mean graduating another 101 new movement disorder specialists. That in turn could reach 78,780 more patients with PD, which could make many very tough situations significantly less tough. PD is one of those things that many people are probably aware of but far fewer know about in detail. You may have heard of the different public figures who have been diagnosed with PD such as Fox who is of Family Ties, Back to the Future and Spin City fame, actor, director, screenwriter and author Alan Alda, well-known athletes like Muhammed Ali, Brian Grant and Davis Phinney, famous singers like Linda Rondstadt, Neil Diamond and Ozzy Osbourne and political figures like the Reverend Jesse Jackson. In fact, you may know someone personally who is dealing with PD. That's because PD is at this moment the second most common and fastest-growing neurological disease in the world. In the U.S., close to 90,000 PD cases are newly diagnosed each year. There's already an estimated 6 million people globally living with PD. Oh, and while in general it's a good thing that life expectancies around the world are getting longer, this does come with some additional considerations PD-wise. Since PD is associated with aging, the world will probably see even more PD cases in the coming years. PD rates are expected to double by the year 2040, which would put further strain on an infrastructure that already is not enough to deal with the current PD numbers. Pictured here are attendees of the 2018 Edmond J. Safra Fellowship Symposium. (Photo: Courtesy of ... More Kristina Magana/Michael J. Fox Foundation) While you may know people with PD, you may not know movement disorder specialists, which is another name for the neurologists with extra training and experience to address PD. That's because the United States has only around 660 movement disorder specialists at this moment. If you do the math, that comes out to only about one such specialist for every 1,000 Medicare beneficiaries with PD. Few people will say, 'Don't worry we've got it covered, there one for every 1,000' about anything. That ratio probably isn't equally spaced around the country either. PD is considered a movement disorder because it can affect how a person is able to move. Symptoms include tremors, rigidness of different body parts, slowing of movements, difficulty initiating movements and postural instability. which is when a person has difficulty maintaining balance and is more likely to fall. There are also non-motor challenges like mood changes as well as difficulty sleeping and thinking. PD is typically progressive, meaning that it gets worse over time. But things can be done to reduce the impact of symptoms and potentially slow the progression. Not everyone will know the latest and greatest on such things, which is why you need specialists. Rachel Dolhun, MD, DipABLM, who is the principal medical advisor for the Michael J. Fox Foundation and a movement disorder specialist herself, explained that while primary care doctors and neurologist who are not movement disorder specialists may be able to offer reasonable care, it makes a difference if you have an expert who has seen many different variations of PD and has PD as a main focus. 'Care is complex,' she explained. 'You need someone involved in your treatment regimen and involving your care team with connections to occupational therapy and physical therapy.' She added that it helps to have someone up on the latest advances, 'Four new treatments got FDA proved. It requires that complexity, knowledge and skill set to implement such treatments in the right people.' Specialists can also help diagnose the condition earlier. Unfortunately, it can take a while for someone with PD to get an official diagnosis. 'Patients find their way to doctors,' said Brooks. 'They often are not aware that specialty care exists.' As a result, patients can end up bouncing around the healthcare system among the wrong kinds of healthcare professionals like a pinball. Along the way, they may even be told that their PD symptoms are nothing, due to something else like anxiety or a musculoskeletal injury or even worse all in their head. Yeah, that's what you want to hear when you've got a real condition that people are just not catching. That doesn't mean that other healthcare professionals are not trying or able to properly PD. It's just that things often can get tricky. 'PD remains a clinical diagnosis,' Dolhun emphasized. That means that you can only diagnose it via putting together different aspects of the patient's history and physical exam. It's not like a broken bone, where there's a clear test to establish the diagnosis. Also, in many cases, particularly at the early stages, the symptoms are not obvious like diarrhea. You won't hear too many people say something like, 'It's not clear that you have diarrhea.' The same can't always be said about PD symptoms. Dolhun said, 'You want an expert who sees PD regularly who can recognize and diagnose it accurately.' Patients can be especially likely to get misdiagnosed when they don't match what's believed to be the 'typical PD profile.' Dolhun explained, 'There's the misperception that it is an old white man's disease.' She added, ' People can be deemed too young for PD. They don't fit the stereotype.' Delayed diagnoses can not only waste time and medical resources but also keep the patient in an uncomfortable limbo. Dolhum related that once patients learn what's really going on they frequently end up feeling 'I don't want this answer but it is nice to have an answer.' Diagnosing someone as soon as possible can then get them into the right treatment programs sooner, which again can make a difference. Pictured here are David Breen, MB, PhD, a Safra Fellow and Susan Fox, MB ChB, MRCP(UK), PhD, a Safra ... More Mentor at the University of Toronto. (Photo: Courtesy of Kristina Magana/Michael J. Fox Foundation) What's been making a difference in making such differences is the Edmond J. Safra Fellowship in Movement Disorders. The Michael J. Fox Foundation and the Edmond J. Safra Foundation partnership has been providing selected academic institutions the funding to offer additional training to neurologists wanting to focus on movement disorders. Each of the institutions then find the right fellow to hire and train. 'The institutions were selected based on their ability to mentor and support the candidates,' said Brooks. 'Diversity and inclusion is important.' She added, 'We started with five centers. Next year, we are expanding to 10 centers. We've essentially doubled the program over the course of 10 years. This is building a network and the next generation of specialists, expanding educational and research collaboration opportunities.' The funding was crucial because PD care and research aren't exactly rolling in the dough. People don't say that they will be entering the movement disorder specialty for the big bucks. Dolhum described care of movement disorder as 'a talking specialty' and that 'talking doesn't get the reimbursement,' compared to procedures. Insurance companies may view talk as cheap. But what movement disorder specialists can do for patients is far from that. 'Getting to a movement specialist early is a sign that you are empowered,' Dolhum emphasized. Both Dolhum and Brooks pointed out how proper specialty care can improve patient outcomes in many different ways. Some of these outcomes may be easy to measure whereas others may be complex. Because, after all, Parkinson's Disease is complex.
Associated Press
29-04-2025
- Health
- Associated Press
The Michael J. Fox Foundation Expands Landmark Parkinson's Research Study toward Better Treatments and Prevention
NEW YORK, April 29, 2025 /PRNewswire/ -- The landmark Parkinson's disease study from The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announces a new expansion with additional cohorts and updated technologies to further explore the intricacies and etiology of this complex neurological disease. First launched in 2010, the Parkinson's Progression Markers Initiative (PPMI) has become a cornerstone of Parkinson's research with the aim of accelerating personalized treatments, cures and one day a world without Parkinson's disease (PD). Now offering additional ways to participate, PPMI has lowered its screening age eligibility and is remotely screening individuals aged 40 or older without PD and people with PD diagnosed within the last seven years for potential longitudinal enrollment at one of 50 sites in 12 countries. Additionally, anyone aged 18 or older in the United States can contribute data on health and wellbeing through the newly relaunched myPPMI study participant platform. This expansion builds on PPMI's longstanding commitment to drive and deepen understanding of the biological fingerprint and clinical footprint of Parkinson's disease. 'Since PPMI began, the study has risen to meet current scientific needs while looking forward to anticipate the infrastructure and novel data required for future research. Partnering with more participants, in the clinics and online, offers new opportunities to develop more tools and learnings to speed therapies while also engaging a broader audience of potential volunteers for the clinical trials to come,' said PPMI's principal investigator and distinguished scientist at the Institute for Neurodegenerative Disorders, Kenneth Marek, MD. PPMI's latest expansion comes as The Michael J. Fox Foundation recognizes extraordinary research progress and an innovative high-risk, high-reward model that has generated more than $2.5 billion dollars to support global research programs. The unprecedented opportunity to speed cures is matched only by the urgency of the need: PD is now the second most common and fastest-growing neurological disease in the world. An estimated 6 million or more people around the world, including over 1 million Americans, live with Parkinson's today. With no way to prevent, stop or slow the disease, PD is projected to double globally by 2040. Expanded Eligibility for In-Clinic Study Population Aims to Answer Key Questions In 2023, PPMI data validated a biomarker test for a key Parkinson's pathology — the aggregation of the protein alpha-synuclein. This groundbreaking new test, the alpha-synuclein seed amplification assay (a-syn SAA), allowed scientists, for the first time, to detect this Parkinson's pathology in living people. The results from PPMI data analysis showed remarkable findings. Firstly, the a-syn SAA test was positive in many people aged 60 or older who were not yet diagnosed with clinical PD and correlated with severe smell loss (≥10% of expected smell ability controlled for age and sex). Six to ten percent of participants in the diagnosed PD cohort had a negative a-syn SAA result. This was most common in people with normal smell ability, and in individuals who carried a PD-associated mutation in the LRRK2 gene. These findings have pointed to a deeper biological understanding of Parkinson's and have led PPMI to adjust its cohorts. Enrolling people aged 40 or older with smell loss and a-syn SAA positivity will allow scientists to study how early this pathology appears, which could help design prevention trials and further understand younger disease onset. PPMI will also further examine the biology of individuals later in disease with a Parkinson's diagnosis within the past seven years and robust smell ability, many presumably negative on the a-syn SAA, to understand the biological markers present in these individuals. 'In science, each answer begets more questions. PPMI is iterating to build on past success and drive to the next breakthrough. These quick pivots are possible only with the trust and commitment of the initiative's many partners. We are grateful for the efforts and contributions of the study team, the scientists, the sites and most importantly the study's generous volunteers who have helped change what we know about this disease and how research is moving to stop it,' said MJFF Chief Program Officer Sohini Chowdhury. Eligible participants — over age 40 and not diagnosed with Parkinson's or over age 30 and diagnosed with Parkinson's in the past seven years — can request a smell test at Online Data Capture Complements In-Clinic Research to Elucidate Brain Health and Disease PPMI has also updated its online experience for participants. In 2020, the study launched an English-language online platform to capture data on health and wellbeing over time from anyone aged 18 or older in the United States, with or without PD. To date, more than 46,000 participants have completed more than 222,000 online study visits, contributing data in over 3.3 million surveys. This data is pointing scientists to predictive features and varied progression profiles, which may help improve care and research practices. The online capture part study has been folded into the myPPMI participant platform. Introduced in 2023, myPPMI provides opportunities for participants to contribute in varied ways to the initiative (e.g., online, in-person) and to contribute study data virtually and, in some cases, individuals' personal research information. In 2024, PPMI began offering access to personal data from the a-syn SAA test, dopamine transporter (DAT) brain imaging scan, and a physician assessment of movement issues. One of the first Parkinson's studies to share back this volume of research information directly to trial volunteers, PPMI provides education and counseling around these tests as well. myPPMI is available in the U.S., Austria, England, Canada, Germany, Spain, the Netherlands, with additional countries starting later in 2025; content is currently translated into German, Dutch and Spanish. The integration of online data collection into myPPMI enhances the participant experience as well as widens the pool of contributors. 'I am grateful for the opportunity to be part of this study community. Joining PPMI has been an empowering step in my Parkinson's journey, and I'm glad that the new platform will make it easy to contribute more to the study,' said PPMI Community Advisory Board member Marty Acevedo, 65, of Oceanside, California. 'Furthermore, I'm glad that the study is now returning some personal research information back to us participant partners. This knowledge on our own disease can help navigate care and research decisions.' PPMI's Continuing Collaborations to Grow Study Impact Today, MJFF is convening hundreds of academic, research and industry leaders from around the world for its PPMI Annual Investigators Meeting held in New York City. Hosted by MJFF, the annual meeting features reports on promising avenues of exploration in the study and advancements in our understanding around disease progression and biomarkers, while addressing challenges and opportunities in clinical trial innovations, including new approaches to integrating patient perspectives. Heralded as 'the study that's changing everything' about how Parkinson's is diagnosed, managed and treated, PPMI and its data are made possible by the nearly 4,000 volunteers — people with PD, disease risk factors and control volunteers — at PPMI clinics and more than 45,000 in its online study. All de-identified data is shared in real-time with qualified scientists to speed scientific discovery and validation of findings toward broad application. While iterating its current protocols, PPMI is also collaborating to grow the impact of its dataset, biosample library and engaged participant base. PPMI is a $750-million public-private partnership. Major funding for PPMI comes from ASAP, a global research initiative focused on accelerating the pace of discovery for Parkinson's disease. ASAP support is enabling expanded PPMI recruitment efforts and remote testing as well as assay development efforts to enable breakthroughs such as αSyn-SAA. This infrastructure provides a ready platform for future discoveries. In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation, Connie and Steven Ballmer, and Susan and Riley Bechtel. The study is additionally funded by a consortium of more than 40 biotech and pharmaceutical firms providing financial and in-kind support, and by tens of thousands of individual donors to The Michael J. Fox Foundation. About The Michael J. Fox Foundation for Parkinson's Research (MJFF) As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $2.5 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open- access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at Facebook, Instagram and LinkedIn. View original content to download multimedia: SOURCE The Michael J. Fox Foundation for Parkinson's Research
